Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
October 10, 2023
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Acrotech Biopharma
Deal Size : $6.6 million
Deal Type : Agreement
Details : The new Agreement grants Acrotech a royalty-free license to belinostat in all other territories including the United States, Canada, Mexico, and India.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : $6.6 million
June 04, 2020
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Acrotech Biopharma
Deal Size : $6.6 million
Deal Type : Agreement
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Bristol Myers Squibb | Acrotech Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 19, 2020
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Bristol Myers Squibb | Acrotech Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Axis Clinicals Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 04, 2019
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Axis Clinicals Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Axis Clinicals Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 12, 2016
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Axis Clinicals Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Axis Clinicals Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 10, 2016
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Axis Clinicals Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Spectrum Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
August 25, 2015
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Spectrum Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 24, 2013
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 24, 2012
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Valerio Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 17, 2011
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Valerio Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable